Despite their rarity compared to other neoplasms, salivary gland tumors (SGTs) are relatively frequent in the context of head and neck tumors (El-Naggar, Chan, Grandis, Takata, & Sootweg, 2017). These lesions comprise a heterogeneous group of benign and malignant neoplasms with significant variability in their microscopic appearance and clinical presentation, and its biological behavior can vary according to the lesion (Fonseca, Sena Filho, Altemani, Speight, & Vargas, 2016). The management of these neoplasms is a challenge due to their unpredictable clinical and biological behavior that may lead to failure in response to treatment (Wagner et al., 2017). Salivary gland tumors represent 5% of all head and neck neoplasms, with an estimated global annual incidence varying from 0.4 to 13.5 cases per 100,000 inhabitants (Fonseca et al., 2012). According to the World Health Organization (WHO) classification of head and neck tumors, there are more than 30 neoplasms recognized (El-Naggar et al., 2017). Mucoepidermoid carcinoma and pleomorphic adenoma are the most frequent malignant and benign neoplasms, respectively (El-Naggar et al., 2017). Several studies have been developed on this topic; however, the etiologic factors are still unknown, although chromosomic translocation, secondary radiation, and chemotherapy may be associated with the development of SGT (El-Naggar et al., 2017). Furthermore, epigenetic alterations have also been suggested as etiological factors, although there are still few studies analyzing its role in SGT (